DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161750

High expression levels of bone morphogenetic protein-2 and p-glycoprotein related with progressivity in patient with osteosarcoma

Ketut Siki Kawiyana, Henry Ricardo Handoyo, I Gede Eka Wiratnaya, I Ketut Suyasa, K. G. Mulyadi Ridia

Abstract


Background: Osteosarcoma progression characterized by the presence of metastasis dan local recurrence. Several studies focused on bone morphogenetic protein-2 (BMP-2) and P-glycoprotein as protein that influence the progression of osteosarcoma, which are characterized by metastasis and local recurrence.

Methods: This study was a cross sectional analytic study. This study looks at the relationship level of BMP-2 and P-glycoprotein with metastasis and local recurrence in osteosarcoma. Twenty three research subjects are paraffin blocks of osteosarcoma patients and secondary data was conducted through medical records to determine metastasis and local recurrence that occurs in these patients.

Results: The result showed significant correlation between BMP-2 and P-glycoprotein with metastasis and local reccurence.

Conclusions: BMP-2 and P-glycoprotein positivity as determined by immunohistochemistry, was a strong correlate of more rapid disease progression. It should be taken into consideration to identify a subgroup of osteosarcoma patients with poor outcome at the time of diagnosis. So it might be an important marker in planning innovative chemotherapeutic regimens.


Keywords


BMP-2, Metastasis, Local Recurrence, Osteosarcoma, P-glycoprotein

Full Text:

PDF

References


Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosarcoma and forthcoming Therapeutic Strategies. Expert Rev. Anticancer Ther. 2007;7(2):169-81.

Bakhshi S, Radhakrishnan V. Prognostic markers in osteosarcoma. Expert Rev. Anticancer Ther. 2010;10(2):271-87.

Gelderblom H, Jinks RC, Sydes M, Bramwell VH, van Glabbeke M, Grimer RJ, H, et al. Survival After Recurrent Osteosarcoma: Data From 3 European Osteosarcoma Intergroup (EOI) Randomized Controlled Trials. Eur J Cancer. 2011;47(6):895-902.

Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K et al. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. Journal of Clinical Oncology. 2002;20(3):776-90.

Franke M, Hardes J, Helmke K, Jundt G, Jürgens H, Kempf-Bielack B, et al. Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer. 2011;56(5):771-6.

Kong C, Hansen MF. Biomarkers in Osteosarcoma. Expert Opin Med Diagn. 2009;3(1):13-23.

Steinert S, Kroll TC, Taubert I, Pusch L, Hortschansky P, Höffken K, et al. Differential expression of cancer-related genes by single and permanent exposure to bone morphogenetic protein 2. J Cancer Res Clin Oncol. 2008;134:1237-45.

Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU,, et al. Osteosarcoma Relapse After Combined Modality Therapy: An Analysis Of Unselected Patients In The Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559-68.

Raida M, Clement JH, Leek RD, Ameri K, Bicknell R, Niederwieser D, et al. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol. 2005;131:741-50.

Yang X, Wang Y, Liu F, Zeng K, Qian M, Chen G, et al. Increased invasiveness of osteosarcoma mesenchymal stem cells induced by bone-morphogenetic protein-2. In Vitro Cell. Dev. Biol.-Animal. 2013;49:270-8.

Wang L, Park P, Marca F, Than K, Rahman S, Lin C. Advancements in Suppression of Osteosarcoma Tumorigenicity: A Prospective Look. Journal of Cancer Therapy. 2012;3:327-30.

Higgins CF. Annu. Rev. Cell Biol. 1992;8:67-113.

Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 1995;333:1380-5.

Chan HSL, Grogan TM, Haddad G, DeBoer G, Ling V. P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy J. Natl. Cancer Inst. 1997;89:1706-15.

Scotlandi K, Manara MC, Serra M. The Expression of P-Glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Onco Gene. 1999;(18):739-46.

Riduwan. Dasar-Dasar Statistika. Bandung: Alfabeta. 2011.

Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue: a review. Diagn Pathol. 2014;9:221.

Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest. 2008;88:1264-77,

Rici REG, Will SEA, Favaron PO, Fratini P, Miglino MA, Ambrósio CE, O et al. Modulation of Angiogenesis and Imune Response in Canine Osteosarcoma by BMP-2 and Mesenchymal Stem Cells. J Stem Cell Res Ther. 2013;3:3.

Pakos EE, Ioannidis JPA. The Association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A Meta-Analysis. Cancer. 2003;1;98(3);581-9.

Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, et al. May P-Glycoprotein status be used to stratify high grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. International Journal Of Oncology. 2006;29:1459-68.

Pakbaz S, Torabi-Nezhad S, Jaberi FM. Clinical Significance of P-Glycoprotein Immunohistochemistry and Histomorphic Factors in Patients with Osteosarcoma. Iranian Red Crescent Medical Journal. 2009;11(3):277-85.

Bacci G, Donati D, Manfrini M, Forni C, Bertoni F, Gherlinzoni F, et al. Local recurrence after surgical or surgicalchemotherapeutic treatment of osteosarcoma of the limbs. Incidence, risk factors and prognosis. Minerva Chir. 1998;53(7-8):619-29.

Briccoli A, Rocca M, Salone M, Bacci G, Ferrari S, Balladelli A, et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer. 2005;104(8):1721-5.